Predictors of hepatitis C treatment response: what's new?

References

• WHO. Hepatitis C Fact sheet. 2013. Available from: www.who.int/mediacentre/factsheets/fs164/en/
   Google Scholar
• Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long term outcome. Semin Liver Dis 2000;20:17-35
   PubMed Web of Science ®Google Scholar
• Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34:593-602
   PubMed Web of Science ®Google Scholar
• Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138(2):513-21
   PubMed Web of Science ®Google Scholar
• Smith BD, Morgan RL, Beckett GA, et al. Hepatitis C virus testing of persons born during 1945 to 1965: recommendation from the Centres for Disease Control and Prevention. Ann Intern Med 2012;157:817-22
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J. Hepatol 2011;55:245-64
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195-206
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405-16
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1207-17
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364(25):2417-28
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357(2):124-34
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140(5):346
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975
   PubMed Web of Science ®Google Scholar
• Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010;30(3):342-55
   PubMed Web of Science ®Google Scholar
• Foster GR, Hézode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011;141(3):881-9
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87
   PubMed Web of Science ®Google Scholar
• Jacobson I, Gordon S, Kowdley K, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Eng J Med 2013;368(20):1867-77
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38
   PubMed Web of Science ®Google Scholar
• Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A Inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010;54(9):3641-50
   PubMed Web of Science ®Google Scholar
• Martinot-Peignoux M, Ripault MP, Maylin S, et al. Optimal pre-treatment viral load cut-off to predict treatment outcome in patients with chronic hepatitis C treated with peginterferon alfa-2b plus ribavirin. J Hepatol 2007;46(Suppl 1):S234
   Google Scholar
• Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139(1):120
   PubMed Web of Science ®Google Scholar
• Berg T, Weich V, Teuber G, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009;50(2):369-77
   PubMedGoogle Scholar
• Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135(2):451-8
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292(23):2839-48
   PubMed Web of Science ®Google Scholar
• Brau N, Rodriguez-Torres M, Prokupek D, et al. Treatment of chronic hepatitis C in HIV/HCV coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. Hepatology 2004;39(4):989-98
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Pol S, Cooper C, et al. Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients. Abstract. Presented at the 19th Conference on Retroviruses and Opportunistic Infections; 6 March 2012; Seattle, WA, USA
   Google Scholar
• Sulkowski MS, Sherman KE, Soriano V, et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR24 final study results. Abstract. Presented at the 63rd annual meeting of the AASLD; 9–13 November 2012; Boston, MA, USA
   Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361(6):580-93
   PubMed Web of Science ®Google Scholar
• Lawitz E, Ghalib R, Rodriguez-Torres M, et al. COSMOS Study: SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders. 20th Conference on Retroviruses and Opportunistic Infections; 3–6 March 2013; Atlanta, GA, USA
   Google Scholar
• Zeuzem S, Dusheiko GM, Riina Salupere R, et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE Trial. Presented at The 64th Annual Meeting of the American Association for the Study of Liver Diseases; 1–5 November 2013; Washington, DC, USA
   Google Scholar
• Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virological response in hepatitis B and C. J Hepatol 2008;49(4):634-51
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41(10):1105-9
   PubMed Web of Science ®Google Scholar
• Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461(7265):399-401
   PubMedGoogle Scholar
• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
   PubMed Web of Science ®Google Scholar
• Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138(4):1338-45
   PubMed Web of Science ®Google Scholar
• Rallón N, Soriano V, Naggie S, et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 2011;25(8):1025-33
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. Abstract 1369. Presented at: 46th Annual Meeting of the European Association for the Study of the Liver; 30 March–3 April 2011; Berlin, Germany
   Google Scholar
• Nelson DR, Poordad F, Feld JJ, et al. High SVR Rates (SVR4) for 12-week total telaprevir combination therapy in IL28B CC treatment-naïves and prior relapsers with G1 chronic hepatitis C: CONCISE interim analysis. Presented at: 48th Annual Meeting of the European Association for the Study of the Liver; 24–28 April 2013; Amsterdam, Holland
   Google Scholar
• Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a novel interferon gene ILNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013;45:164-71
   PubMed Web of Science ®Google Scholar
• Franco S, Aparicio E, Parera M, et al. IFNL4 ss469415590 variant is a better predictor than IFNL3 (IL28B) rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C/HIV-1 co-infected patients. AIDS 2013; Epub ahead of print
   Google Scholar
• Lupberger J, Felmlee D, Baumert T. Interferon-Lambda Polymorphisms and hepatitis C clearance revisited. Hepatology 2013;58(1):439-41
   PubMedGoogle Scholar
• Lagging M, Askarieh G, Negro F, et al. DITTO-HCV Study Group. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 2011;6(2):e17232
   PubMed Web of Science ®Google Scholar
• Suppiah V, Gaudieri S, Armstrong NJ, et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med 2011;8(9):e1001092
   PubMed Web of Science ®Google Scholar
• Arnaud C, Pradat P. Spaziante, et al. Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes. Antivir Ther 2013; Epub ahead of print
   PubMedGoogle Scholar
• Pol S, Aerssens J, Zeuzem S, et al. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol 2013;58:883-9
   PubMedGoogle Scholar
• Medrano J, de Ledinghen V, Taupin J-L, et al. Baseline prediction of response to pegIFN-RBV in chronic hepatitis C using the Prometheus score. Abstract 657. 63rd AASLD; 9–13 November 2012; Boston, MA, USA
   Google Scholar
• Mangia A, Thompson AJ, Santoro R, et al. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 2011;54(3):772-80
   PubMed Web of Science ®Google Scholar
• Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012;143(3):608-18
   PubMed Web of Science ®Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365(11):1014-24
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Marcellin P, Zeuzem S, et al. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology 2012;56(2):567-75
   PubMedGoogle Scholar
• Almerighi C, Sinistro A, Cavazza A, et al. 1Alpha,25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes. Cytokine 2009;45(3):190-7
   PubMedGoogle Scholar
• Petta S, Cammà C, Scazzone C, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010;51:1158-67
   PubMed Web of Science ®Google Scholar
• Baur K, Mertens JC, Schmitt J, et al. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients. Antivir Ther 2012;17(3):541-7
   PubMed Web of Science ®Google Scholar
• Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World J Gastroenterol 2012;18(8):800-5
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123(4):1061-9
   PubMed Web of Science ®Google Scholar
• Gordon SC, Yoshida EM, Lawitz EJ, et al. Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther 2013;38(1):16-27
   PubMedGoogle Scholar
• Manns M, Marcellin P, Poordad F, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: results from QUEST-2 a Phase III trial. Abstract 1413. (EASL 2013). 48th Annual Meeting of the European Association for the Study of the Liver; 24–28 April 2013; Amsterdam, The Netherlands
   Google Scholar
• Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: results from QUEST-1 a Phase III trial. Abstract 1425. (EASL 2013). 48th Annual Meeting of the European Association for the Study of the Liver; 24–28 April 2013; Amsterdam, The Netherlands
   Google Scholar
• Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-24
   PubMed Web of Science ®Google Scholar
• Chu TW, Kulkarni R, Gane EJ, et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012;142:790-5
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013;69:630-9
   Google Scholar
• Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013;368:45-53
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype1 infection. abstract LB-1. Annual Meeting of the American Association for the Study of Liver Diseases; 9–13 November 2012; Boston, MA, USA
   Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without Ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3. Abstract LB-2. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012); 9–13 November 2012; Boston, MA, USA
   Google Scholar